Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.44 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857284 | 0.87 | HTT (0.55) | CYP17A1CYP1A2CYP2C19SMN1; SMN2KCNQ4 | |
| SCHEMBL18254450 | 0.86 | CYP17A1 (0.46) | CYP17A1HPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2363945 | 0.86 | CYP17A1 (0.53) | CYP17A1KCNQ4KCNQ5RXFP1LMNA | |
| SCHEMBL29834708 | 0.86 | CYP17A1 (0.53) | CYP17A1KCNQ4KCNQ5RXFP1LMNA | |
| SCHEMBL17616117 | 0.84 | KMT2A (0.52) | CYP17A1HPGDSMN1; SMN2RXFP1LMNA | |
| SCHEMBL31347221 | 0.84 | CYP17A1 (0.52) | CYP17A1SMN1; SMN2KCNQ4KCNQ5RXFP1 | |
| SCHEMBL64834 | 0.84 | AAK1 (0.53) | CYP17A1HPGDSMN1; SMN2LMNAHTT | |
| SCHEMBL478362 | 0.84 | CYP17A1 (0.52) | CYP17A1SMN1; SMN2KCNQ4KCNQ5RXFP1 | |
| SCHEMBL2833050 | 0.84 | CYP17A1 (0.52) | CYP17A1KCNQ4KCNQ5RXFP1LMNA | |
| SCHEMBL29659087 | 0.84 | CYP17A1 (0.52) | CYP17A1SMN1; SMN2KCNQ4KCNQ5RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427556-B2 | Urea derivatives as inhibitors of ASK1 | Hepagene Therapeutics (HK) Limited (HK) | 2022-08-30 | — | — | US | disclosed |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
| EP-3710441-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | Hepagene Therapeutics, Inc. (VG) | 2020-09-23 | — | — | EP | disclosed |
| CN-111433198-A | Urea derivatives as inhibitors of ASK1 | 合帕吉恩治疗公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-2229391-B1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427556-B2 | Urea derivatives as inhibitors of ASK1 | ATF1, ERN1, MAP3K1 | CYP17A1 3573/4885HPGD 1722/4885CYP1A2 3081/4885 |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | CYP17A1 3573/4885HPGD 1722/4885CYP1A2 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.